Nanogen announced today its subsidiary, Epoch Biosciences, was issued Patent No. 6,951,930, "Hybridization-Triggered Fluorescent Detection of Nucleic Acids" by the U.S. Patent and Trademark Office.
Arena Pharmaceuticals has announced that it was issued US patent number 6,953,787, entitled "5-HT2C Receptor Modulators," by the United States Patent and Trademark Office. The patent relate
Nabi Biopharmaceuticals has announced that it has been granted U.S. Patent No. 6,936,258 entitled "Staphylococcus Antigen and Vaccine" by the U.S. Patent and Trademark Office for the composition of a str
Third Wave Technologies has announced that it has filed two patent suits in federal court in Madison, Wis. The company last Friday filed suit against Digene Corp., seeking a court ruling supportin
Ichor Medical Systems today announced that it has been issued a patent that protects vital elements of the company's technology. U.S. Patent Number 6,912,417 entitled, "Method and Apparatus fo
Domantis Limited, the human Domain Antibody Therapeutics company, has successfully opposed European patent number EP0656946, leading to a major amendment of the main claim in the patent and a signifi
A CSIRO innovation for determining gene function quickly and with virtually 100 per cent efficiency has been granted a US patent clarifying its leadership position in the international gene silencing are
Generex Biotechnology Corporation today announced that it has been granted a patent by the Australian Patent Office titled "Mixed Micellar Pharmaceutical Delivery System and Method of Preparation."
Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antige
Generex Biotechnology Corporation has announced that it has been granted a patent by the Canadian Intellectual Property Office titled "Mixed Micellar Delivery System and Method of Preparation."
BioLife President and CEO John G. Baust, Ph.D., said that the market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification or freezing rapidly to avoid the presence of ice crystals.
Baust said, "Our core preservation technologies can be a critical factor in applying this new technology and solidifying our patent position in that area gives us a commercial foothold as that market develops." He continued, "We believe BioLife holds a unique and encompassing intellectual property position in the biological processing and preservation of cells, tissues and organs and that our technology significantly improves the viability of cells and organs for longer periods of time during transportation and storage."
The issuance of the patent specifically provides BioLife with the latest extension of its molecular-based cryopreservation technology platform and protects BioLife's use of cell death inhibitors (calpain inhibitors) in hypothermic preservation solutions necessary to improve cryopreservation outcome. With this patent the scope of the Company's proprietary preservation technology extends into the cell, tissue and organ vitrification arena by including the Company's molecular-based approaches to preservation to prevent apoptotic and necrotic cell death following the preservation process.
This patent, No. 6,921,633, titled, "Methods and compositions for the preservation of cells, tissues or organs in the vitreous state," brings the total number of issued patents that relate to its preservation solutions to four.
http://www.biolifesolutions.com/